Multivariate analysis for factors affecting acute GVHD, chronic GVHD, engraftment, leukemia relapse, and mortality
| Outcome and significant factor* . | Hazard risk (95% CI) . | P . |
|---|---|---|
| Acute GVHD (grade III or IV)† | ||
| HLA-C allele (match vs mismatch) | 1.85 (1.42-2.41) | < .001 |
| HLA-A allele (match vs mismatch) | 1.58 (1.20-2.09) | .001 |
| HLA-B allele (match vs mismatch) | 1.43 (1.01-2.01) | .041 |
| HLA-DRB1 allele (match vs mismatch) | 1.42 (1.07-1.90) | .017 |
| Chronic GVHD† | ||
| HLA-A/B allele‡ (match vs mismatch) | 1.45 (1.13-1.85) | .003 |
| Patient age (linear) | 1.014 (1.003-1.024) | .006 |
| Engraftment† | ||
| HLA class I allele2-155 (match vs mismatch) | 0.86 (0.76-0.96) | .011 |
| Transplanted cell number (linear) | 1.00047 (1.00007-1.00088) | .023 |
| Disease (ALL vs CML) | 0.79 (0.69-0.90) | .001 |
| Leukemia relapse2-153 | ||
| Risk (standard risk vs high risk) | 3.40 (2.43-4.76) | < .001 |
| Mortality2-153 | ||
| HLA-A allele (match vs mismatch) | 1.63 (1.35-1.97) | < .001 |
| HLA-B allele (match vs mismatch) | 1.33 (1.04-1.70) | .022 |
| Patient age (linear) | 1.019 (1.012-1.026) | < .001 |
| Risk of leukemia relapse (standard vs high) | 2.05 (1.72-2.45) | < .001 |
| GVHD prophylaxis (cyclosporine vs ATG) | 1.39 (1.03-1.89) | .030 |
| Outcome and significant factor* . | Hazard risk (95% CI) . | P . |
|---|---|---|
| Acute GVHD (grade III or IV)† | ||
| HLA-C allele (match vs mismatch) | 1.85 (1.42-2.41) | < .001 |
| HLA-A allele (match vs mismatch) | 1.58 (1.20-2.09) | .001 |
| HLA-B allele (match vs mismatch) | 1.43 (1.01-2.01) | .041 |
| HLA-DRB1 allele (match vs mismatch) | 1.42 (1.07-1.90) | .017 |
| Chronic GVHD† | ||
| HLA-A/B allele‡ (match vs mismatch) | 1.45 (1.13-1.85) | .003 |
| Patient age (linear) | 1.014 (1.003-1.024) | .006 |
| Engraftment† | ||
| HLA class I allele2-155 (match vs mismatch) | 0.86 (0.76-0.96) | .011 |
| Transplanted cell number (linear) | 1.00047 (1.00007-1.00088) | .023 |
| Disease (ALL vs CML) | 0.79 (0.69-0.90) | .001 |
| Leukemia relapse2-153 | ||
| Risk (standard risk vs high risk) | 3.40 (2.43-4.76) | < .001 |
| Mortality2-153 | ||
| HLA-A allele (match vs mismatch) | 1.63 (1.35-1.97) | < .001 |
| HLA-B allele (match vs mismatch) | 1.33 (1.04-1.70) | .022 |
| Patient age (linear) | 1.019 (1.012-1.026) | < .001 |
| Risk of leukemia relapse (standard vs high) | 2.05 (1.72-2.45) | < .001 |
| GVHD prophylaxis (cyclosporine vs ATG) | 1.39 (1.03-1.89) | .030 |
For abbreviations, see Table 1.
The variables entered in each stepwise analysis were sex (donor-recipient pairs), patient age, donor age, diagnosis, risk of leukemia relapse, graft-versus-host disease prophylaxis, preconditioning, transplanted cell dose, and matching of HLA-A, -B, -C, -DRB1, -DQB1 alleles (see Table 1 and the matching of HLA allele between patient and donor in “Patients, materials, and methods”). The significant level of HLA matching in each event is shown in this table.
Analyzed in all cases.
HLA-A and/or HLA-B allele.
Analyzed in leukemia cases.
HLA-A, HLA-B, and/or HLA-C allele.